Literature DB >> 34310832

Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline.

Michelle M Mielke1,2, Jeremiah A Aakre1, Alicia Algeciras-Schimnich3, Nicholas K Proctor4, Mary M Machulda5, Udo Eichenlaub6, David S Knopman2, Prashanthi Vemuri7, Jonathan Graff-Radford2, Clifford R Jack7, Ronald C Petersen1,2, Jeffrey L Dage4.   

Abstract

INTRODUCTION: The prognostic utility of cerebrospinal fluid (CSF) phosphorylated tau 217 (p-tau217) and p-tau181 is not understood.
METHODS: Analyses included 753 Mayo Clinic Study on Aging participants (median age = 71.6; 57% male). CSF amyloid beta (Aβ)42 and p-tau181 were measured with Elecsys immunoassays. CSF p-tau181 and p-tau217 were also measured with Meso Scale Discovery (MSD). We used Cox proportional hazards models for risk of mild cognitive impairment (MCI) and linear mixed models for risk of global and domain-specific cognitive decline and cortical thickness. Analyses were stratified by elevated brain amyloid based on CSF Aβ42 or amyloid positron emission tomography for those with imaging.
RESULTS: CSF p-tau217 was superior to p-tau181 for the diagnosis of Alzheimer's disease (AD) pathology. CSF MSD p-tau181 and p-tau217 were associated with risk of MCI among amyloid-positive individuals. Differences between CSF p-tau measures predicting cortical thickness were subtle. DISCUSSION: There are subtle differences for CSF p-tau217 and p-tau181 as prognostic AD markers.
© 2021 the Alzheimer's Association.

Entities:  

Keywords:  biomarker; cerebrospinal fluid; cognitive decline; dementia; mild cognitive impairment; phosphorylated tau; prognosis

Mesh:

Substances:

Year:  2021        PMID: 34310832      PMCID: PMC8789950          DOI: 10.1002/alz.12415

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   16.655


  31 in total

1.  Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid.

Authors:  Valeria Lifke; Gwendlyn Kollmorgen; Ekaterina Manuilova; Tobias Oelschlaegel; Lars Hillringhaus; Monika Widmann; Christine A F von Arnim; Markus Otto; Robert H Christenson; Jennifer L Powers; Leslie M Shaw; Oskar Hansson; James D Doecke; Qiao-Xin Li; Charlotte Teunissen; Hayrettin Tumani; Kaj Blennow
Journal:  Clin Biochem       Date:  2019-05-23       Impact factor: 3.281

2.  Comparison of 18F-FDG and PiB PET in cognitive impairment.

Authors:  Val J Lowe; Bradley J Kemp; Clifford R Jack; Matthew Senjem; Stephen Weigand; Maria Shiung; Glenn Smith; David Knopman; Bradley Boeve; Brian Mullan; Ronald C Petersen
Journal:  J Nucl Med       Date:  2009-05-14       Impact factor: 10.057

Review 3.  CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.

Authors:  Bob Olsson; Ronald Lautner; Ulf Andreasson; Annika Öhrfelt; Erik Portelius; Maria Bjerke; Mikko Hölttä; Christoffer Rosén; Caroline Olsson; Gabrielle Strobel; Elizabeth Wu; Kelly Dakin; Max Petzold; Kaj Blennow; Henrik Zetterberg
Journal:  Lancet Neurol       Date:  2016-04-08       Impact factor: 44.182

4.  Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.

Authors:  Harald Hampel; Katharina Buerger; Raymond Zinkowski; Stefan J Teipel; Alexander Goernitz; Niels Andreasen; Magnus Sjoegren; John DeBernardis; Daniel Kerkman; Koichi Ishiguro; Hideto Ohno; Eugeen Vanmechelen; Hugo Vanderstichele; Cheryl McCulloch; Hans-Jurgen Moller; Peter Davies; Kaj Blennow
Journal:  Arch Gen Psychiatry       Date:  2004-01

5.  Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology.

Authors:  Kaj Blennow; Chun Chen; Claudia Cicognola; Kristin R Wildsmith; Paul T Manser; Sandra M Sanabria Bohorquez; Zhentao Zhang; Boer Xie; Junmin Peng; Oskar Hansson; Hlin Kvartsberg; Erik Portelius; Henrik Zetterberg; Tammaryn Lashley; Gunnar Brinkmalm; Geoffrey A Kerchner; Robby M Weimer; Keqiang Ye; Kina Höglund
Journal:  Brain       Date:  2020-02-01       Impact factor: 13.501

6.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

Authors:  Clifford R Jack; Val J Lowe; Matthew L Senjem; Stephen D Weigand; Bradley J Kemp; Maria M Shiung; David S Knopman; Bradley F Boeve; William E Klunk; Chester A Mathis; Ronald C Petersen
Journal:  Brain       Date:  2008-02-07       Impact factor: 13.501

7.  The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics.

Authors:  Rosebud O Roberts; Yonas E Geda; David S Knopman; Ruth H Cha; V Shane Pankratz; Bradley F Boeve; Robert J Ivnik; Eric G Tangalos; Ronald C Petersen; Walter A Rocca
Journal:  Neuroepidemiology       Date:  2008-02-07       Impact factor: 3.282

8.  Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease.

Authors:  Niklas Mattsson-Carlgren; Emelie Andersson; Shorena Janelidze; Rik Ossenkoppele; Philip Insel; Olof Strandberg; Henrik Zetterberg; Howard J Rosen; Gil Rabinovici; Xiyun Chai; Kaj Blennow; Jeffrey L Dage; Erik Stomrud; Ruben Smith; Sebastian Palmqvist; Oskar Hansson
Journal:  Sci Adv       Date:  2020-04-15       Impact factor: 14.136

9.  CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease.

Authors:  Shorena Janelidze; Henrik Zetterberg; Niklas Mattsson; Sebastian Palmqvist; Hugo Vanderstichele; Olof Lindberg; Danielle van Westen; Erik Stomrud; Lennart Minthon; Kaj Blennow; Oskar Hansson
Journal:  Ann Clin Transl Neurol       Date:  2016-01-01       Impact factor: 4.511

10.  Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease.

Authors:  Shorena Janelidze; Erik Stomrud; Ruben Smith; Sebastian Palmqvist; Niklas Mattsson; David C Airey; Nicholas K Proctor; Xiyun Chai; Sergey Shcherbinin; John R Sims; Gallen Triana-Baltzer; Clara Theunis; Randy Slemmon; Marc Mercken; Hartmuth Kolb; Jeffrey L Dage; Oskar Hansson
Journal:  Nat Commun       Date:  2020-04-03       Impact factor: 14.919

View more
  2 in total

Review 1.  Tauopathies: new perspectives and challenges.

Authors:  Yi Zhang; Kai-Min Wu; Liu Yang; Qiang Dong; Jin-Tai Yu
Journal:  Mol Neurodegener       Date:  2022-04-07       Impact factor: 14.195

Review 2.  Dissecting the clinical heterogeneity of early-onset Alzheimer's disease.

Authors:  Daniel W Sirkis; Luke W Bonham; Taylor P Johnson; Renaud La Joie; Jennifer S Yokoyama
Journal:  Mol Psychiatry       Date:  2022-04-07       Impact factor: 13.437

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.